Breaking News

Synteract To Acquire HCR

December 20, 2012

Gains resources and scale to support large, global CRO programs

Synteract, a portfolio company of Gryphon Investors, has entered into a definitive agreement to acquire Harrison Clinical Research (HCR), headquartered in Munich, Germany, with operations in Europe, Israel and South America, and Princeton, NJ. Synteract plans to combine operations to become a global service provider. The transaction, subject to customary closing conditions, is expected to close in 1Q13.
 
Through the acquisition, Synteract gains a clinical in-patient unit in Germany and a clinical research training center in Belgium, as well as early phase and clinical pharmacology services, Phase II-IV capabilities, and a functional service provision.
 
Wendel Barr, Synteract’s chief executive officer, will lead the combined companies. Dr. Francisco Harrison, HCR’s chairman and founder, will remain a senior member of the executive team and become a member of the board of directors. The HCR management will remain in place.
 
“Harrison Clinical Research is an exceptional fit for Synteract, uniting two well-respected players with longstanding drug development expertise to form a new global leader with enhanced scale and therapeutic breadth,” said Mr. Barr. “Together we will provide a continuum of service that allows us to work with clients throughout their entire development life cycle, from emerging products through post-marketing.”
 
Dr. Harrison added, “HCR has a long tradition of outstanding customer service, as does Synteract. We see this as a growth opportunity that allows us to continue providing our customers with the same personalized service they have come to expect, but on a larger geographic scale. Our shared company cultures and flexible, customizable approaches to managing clinical trials make this a natural fit for us and ensure our clients will continue receiving the same expertise and excellent customer service worldwide.”

Fairmount Partners, through managing director Neal McCarthy, represented Synteract in a focused acquisition search and on the transaction with Harrison Clinical Research.

blog comments powered by Disqus
  • Cold Chain Packaging Trends

    Cold Chain Packaging Trends

    Kristin Brooks, Contract Pharma||February 4, 2016
    Susan Li of UPS discusses supply chain trends, challenges, and packaging innovations

  • Packaging Equipment Trends Preview

    Packaging Equipment Trends Preview

    Kristin Brooks, Contract Pharma||January 26, 2016
    Christian Treitel of Bosch Packaging Technology discusses trends and capabilities

  • Filings Update

    Filings Update

    December 1, 2015
    Roche, Pfizer, Janssen, BMS and more

  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016